Welcome to our dedicated page for Ehave news (Ticker: EHVVF), a resource for investors and traders seeking the latest updates and insights on Ehave stock.
The Ehave Inc. (EHVVF) news feed on Stock Titan aggregates company communications and related updates that describe its evolution into an applied artificial intelligence platform operator. Recent press releases highlight Ehave’s acquisition of AIHeadHunter, an AI-powered recruitment platform designed to automate and streamline executive search and talent sourcing through advanced data analysis. These announcements provide insight into how Ehave is repositioning itself around data-driven technology assets and AI-enabled business models.
News linked to Ehave also frequently references its subsidiary AIBotics, Inc. (traded as AIBT), which is described as a developer and manager of AI- and robotics-enhanced technologies. AIBotics press releases cover topics such as the development and pilot deployment of the Phill Robot™ massage robot, the Milkyway smart refrigerator, and partnerships aimed at distributing service robots in markets like Israel and Jamaica. These items illustrate how Ehave’s subsidiary is working with AI, robotics, and agentic AI concepts to build products and platforms for wellness, service environments, and intelligent automation.
Investors and observers using this news page can review how Ehave describes its strategic realignment, including its focus on incubating scalable AI platforms and structuring transactions to support that shift. Coverage includes acquisition terms for AIHeadHunter, descriptions of the technology licensed for that platform, and statements about Ehave’s plans to fund and launch enterprise pilots. For AIBotics, the news flow includes product development milestones, collaboration agreements for UI/UX and operating platforms, and early commercialization efforts such as pilot programs in fitness and wellness facilities.
By following the EHVVF news page, readers can see how Ehave communicates its progress on AIHeadHunter, its relationship with AIBotics, and its broader approach to applied AI and robotics. The articles provide context on the company’s stated objectives, the markets it is targeting through its platforms, and the partnerships it reports as part of its growth plans.
Ehave, Inc. (OTC Pink: EHVVF) has licensed advanced AI technology from Vastmindz to enhance its MetaHealthU offerings. Set to monetize this technology in 2022, Ehave aims to integrate features in its Ehave Dashboard to monitor vital statistics such as Heart Rate and Oxygen Saturation through facial light absorption analysis. Vastmindz's CEO recently showcased their innovation on the Unicorn Hunters platform, a show with over 14.5 million viewers, receiving positive remarks from tech experts like Steve Wozniak. This partnership is positioned to broaden healthcare accessibility globally.
Ehave, Inc. (EHVVF) has launched KetaDASH, a managed service offering in-home ketamine therapy for patients with treatment-resistant mental health issues. The service starts in the San Francisco Bay Area and Greater Sacramento Area, with plans to expand. KetaDASH focuses on safety and patient comfort, featuring a team of qualified professionals providing treatments after an initial telemedicine consultation. This initiative aims to broaden access to ketamine therapy, which has shown promise in treating conditions like depression and PTSD, thereby enhancing patient outcomes.
Ehave, Inc. (OTC Pink: EHVVF) announced the acquisition of Rejuv IV, enhancing its KetaDASH brand. This mobile IV therapy provider, active in the San Francisco Bay Area, offers services such as Ketamine treatments and IV Vitamin Therapy. CEO Ben Kaplan emphasized the company's commitment to mental health, highlighting KetaDASH’s role in providing lifesaving treatments for psychiatric disorders like depression and PTSD. The service combines at-home administration with telehealth supervision, expanding Ehave's reach in mental health therapeutics.
Ehave, Inc. (EHVVF) shares insights in a letter to shareholders from CEO Ben Kaplan, highlighting advancements in digital therapeutics for mental health using psychedelics. The company emphasizes mental health issues affecting millions in the U.S. and aims to enhance treatments. Key developments from 2021 include a strengthened balance sheet and successful product development. With plans to monetize technology through licensing, Ehave anticipates significant growth. Additionally, Ehave will distribute 30% of PSLY.COM holdings to shareholders and targets launching the KetaDASH home delivery service soon.
Ehave has signed a Letter of Intent (LOI) with Ei.Ventures to explore a merger forming PSLY.COM, an estimated $360 million transaction. As part of this process, Ehave plans to spin out 30% of its Mycotopia Therapies shares to existing shareholders. Ehave currently holds approximately 9.8 million shares of Mycotopia, which focuses on psilocybin-based therapeutics. The merged companies aim to list on NASDAQ after completing pre-clinical trials for their flagship product, Psilly. This move is seen as a strategic shift towards enhancing shareholder value and market presence.
Ehave, Inc. (EHVVF) announced its KetaDASH platform will sponsor the 2021 Psychedelic Investor Guide. KetaDASH is an IV-based home delivery service for ketamine therapy aimed at enhancing patient care. CEO Ben Kaplan highlighted the platform's HIPAA compliance and early market entry. The Investor Guide features 46 prominent companies in the psychedelic sector, providing essential investment data, including stock charts and financial information. This comprehensive guide will be updated monthly and aims to simplify research for investors in the rapidly developing psychedelic investment landscape.
Ehave, based in Miami, has initiated a ketamine clinical trial aimed at exploring the potential of ketamine to promote neuroplasticity and address mental health issues. The company has engaged KGK Science Inc. to develop the necessary protocol and Informed Consent Form for its Institutional Review Board application. The trial will involve four ketamine infusions for each patient, with the goal of obtaining objective data to support the treatment's effectiveness for depression and related conditions. Ehave also plans to expand its KetaDASH platform to enhance mental health care.
Ehave, Inc. (OTC Pink: EHVVF) announced on September 30, 2021, that the Psychedelic Stock Review has initiated coverage of the company. Ehave is set to launch a range of digital tools aimed at enhancing the effectiveness of Psychedelic treatments. The company previously sold its Clinical Software Platform for $3.2 million and is transitioning to provide patient reporting services in the Psychedelic sector. Key upcoming products include KetaDash, MegaTeam, and the Ehave Health Records Dashboard, all designed to improve patient monitoring and data collection in the growing market for Psychedelic therapies.
Ehave (OTC Pink: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors, announced its inclusion in the 2021 Psychedelic Investor Guide. This guide features leading companies in the emerging psychedelics medicine industry, showcasing Ehave's strategy of integrating digital therapeutics with psychedelic medicine. President Ben Kaplan emphasized that this recognition boosts investor awareness and highlights the company's significant initiatives. The guide aims to familiarize investors with key companies, further validating the potential for success in the psychedelics sector.
Ehave, Inc. (OTC Pink: EHVVF) announced the addition of Dr. Rahul Dixit to its Medical Advisory Board. Dr. Dixit, a Gastroenterology Specialist with over 17 years in the medical field, will advise on human trials for cognitive and psychedelic opportunities and mental health analytical platforms. His expertise in gastrointestinal ailments, particularly those linked to mental health, aligns with Ehave's focus on digital therapeutics for brain disorders. CEO Ben Kaplan expressed confidence in Dr. Dixit's valuable contributions as the company expands its operations.
FAQ
What is the current stock price of Ehave (EHVVF)?
What is the market cap of Ehave (EHVVF)?
